|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reserpine#Warnings]] |
| {{Reserpine}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==PRECAUTIONS==
| |
| | |
| ===General===
| |
| | |
| Since reserpine increases gastrointestinal motility and secretion, it should be used cautiously in patients with a history of [[peptic ulcer]], [[ulcerative colitis]], or [[gallstones ]]([[biliary colic]] may be precipitated).
| |
| | |
| Caution should be exercised when treating hypertensive patients with renal insufficiency, since they adjust poorly to lowered blood pressure levels.
| |
| | |
| Preoperative withdrawal of reserpine does not assure that circulatory instability will not occur. It is important that the anesthesiologist be aware of the patient’s drug intake and consider this in the overall management, since [[hypotension ]]has occurred in patients receiving [[rauwolfia ]]preparations. Anticholinergic and/or adrenergic drugs (e.g., [[metaraminol]], [[norepinephrine]]) have been employed to treat adverse vagocirculatory effects.
| |
| | |
| ===Information for Patients===
| |
| | |
| Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed.
| |
| | |
| ===Drug Interactions===
| |
| | |
| MAO inhibitors should be avoided or used with extreme caution.
| |
| | |
| Concurrent use of [[tricyclic antidepressants]] may decrease the antihypertensive effect of reserpine.
| |
| | |
| Concurrent use of reserpine and direct-or-indirect acting sympathomimetics should be closely monitored. The action of direct-acting amines ([[epinephrine]], [[isoproterenol]], [[phenylephrine]], [[metaraminol]]) may be prolonged when given to patients taking reserpine. The action of indirect-acting amines ([[ephedrine]], [[tyramine]], [[amphetamines]]) is inhibited.
| |
| | |
| Reserpine should be used cautiously with digitalis and quinidine, since cardiac arrhythmias have occurred with rauwolfia preparations. | |
| | |
| Concomitant use of reserpine with other [[antihypertensive ]]agents necessitates careful titration of dosage with each agent.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RESERPINE TABLET [EON LABS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | publisher = | date = | accessdate = 7 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |